Please provide your email address to receive an email when new articles are posted on . Patient experts expressed excitement over ensifentrine’s ability to lower exacerbations. If priced between ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly approved drugs—and often declared them overpriced—companies in the industry ...

Please provide your email address to receive an email when new articles are posted on . Ensifentrine plus maintenance therapy yielded multiple benefits in patients with moderate to severe COPD. If ...

Issuing a preliminary report on the value of GLP-1 treatments, drug pricing watchdog the Institute for Clinical and Economic Review (ICER) said on Tuesday that popular weight loss drugs semaglutide ...

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide ...

ICER rates semaglutide and tirzepatide as cost effective vs lifestyle modifications Lilly's tirzepatide shows "promising but inconclusive" cost-effectiveness vs Novo's semaglutide Net prices of both ...

WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...